• Moderately severe to severe infections of upper respiratory tract, scarlet fever, erysipelas and skin and soft-tissue infections caused by streptococcal Group A:
    • IM 2.4 million units *1 OR
      • Divided dosage administration into multiple site
    • IM 1.2 million units on day 1, then repeat dose on day 3
  • Pneumococcal Infections (NOT for pneumococcal meningitis):
    • IM 1.2 million units OD
      • Repeat every 2-3 days until temperature is normal for 48 hours
  • Injection:
    • 600,000 IU/300,000 IU/ 300,000 IU
  • For IM administration:
    • Do not inject near artery or nerve (may result in permanent neurologic damage)
    • Neonates, infants, small children: Mid-lateral aspect of thigh preferable
    • Older children and adults: Deep IM injection in upper outer quadrant of buttock
    • Because of high concentration of suspended matter, needle may be blocked if injection is not made at slow, steady rate

Exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable.

  • Hypersensitivity reactions
  • Pseudomembranous colitis
  • Hypersensitivity to class/components

WARNING

  • NOT for use IV
  • Do not inject IV or admix with other IV solutions
  • Reports of inadvertent IV administration associated with cardiorespiratory arrest and death
  • None restricted

                                   Drug Status

Availability Prescription only
Pregnancy Use with caution
Breastfeeding Use with caution
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Retardpen 600,000 IU + 300,000 IU + 300,000 IU Injection 1’s Medisel Kenya Medisel Kenya
Drepene 6:3:3 600,000 IU + 300,000 IU + 300,000 IU Injection 1’s Crown Healthcare Crown Healthcare